Cargando…
Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
BACKGROUND AND AIM: Cytokine release syndrome is a dangerous complication of the coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety of tofacitinib in the management of this complication. METHODS: The retrospective study included COVID-19 patients with C-reactiv...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137353/ https://www.ncbi.nlm.nih.gov/pubmed/34023513 http://dx.doi.org/10.1016/j.pupt.2021.102039 |
_version_ | 1783695606415360000 |
---|---|
author | Maslennikov, Roman Ivashkin, Vladimir Vasilieva, Ekaterina Chipurik, Maxim Semikova, Polina Semenets, Victoria Russkova, Tatyana Levshina, Anna Grigoriadis, Diana Magomedov, Shamil Efremova, Irina Dzhakhaya, Natiya |
author_facet | Maslennikov, Roman Ivashkin, Vladimir Vasilieva, Ekaterina Chipurik, Maxim Semikova, Polina Semenets, Victoria Russkova, Tatyana Levshina, Anna Grigoriadis, Diana Magomedov, Shamil Efremova, Irina Dzhakhaya, Natiya |
author_sort | Maslennikov, Roman |
collection | PubMed |
description | BACKGROUND AND AIM: Cytokine release syndrome is a dangerous complication of the coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety of tofacitinib in the management of this complication. METHODS: The retrospective study included COVID-19 patients with C-reactive protein (CRP) levels of 60–150 mg/L. RESULTS: Thirty-two patients who received tofacitinib (TOF group) and 30 patients who did not receive any anti-cytokine drugs (control [CON] group) were enrolled. Mortality and the incidence of admission to the intensive care unit were lower in the TOF group than in the CON group (16.6% vs. 40.0%, p = 0.009; and 15.6% vs. 50.0%, p = 0.004). There was a significant decrease in the volume of the affected part of the lungs (p = 0.022) and a significant increase in oxygen saturation (p = 0.012) in the TOF group than in the CON group 7–10 days after the beginning tofacitinib administration. CRP level was lower in the TOF group than in the CON group (7 [3–22] vs. 20 [5–52] mg/L; p = 0.048) 7–10 days after the start of the administration of tofacitinib. During this period, the number of patients requiring mechanical ventilation or those in the prone position increased in the CON group compared to those in the TOF group (26.7% vs. 0.0%, p = 0.002; 33.3% vs. 6.7%, p = 0.020). There was no significant difference in the development of secondary infections, liver or kidney injury, and cytopenia between the two groups. CONCLUSION: Tofacitinib was effective and safe for managing the cytokine release syndrome in COVID-19. Randomized controlled double-blind trials with tofacitinib with and without the simultaneous use of glucocorticoids are required to confirm our findings. |
format | Online Article Text |
id | pubmed-8137353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81373532021-05-21 Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19 Maslennikov, Roman Ivashkin, Vladimir Vasilieva, Ekaterina Chipurik, Maxim Semikova, Polina Semenets, Victoria Russkova, Tatyana Levshina, Anna Grigoriadis, Diana Magomedov, Shamil Efremova, Irina Dzhakhaya, Natiya Pulm Pharmacol Ther Article BACKGROUND AND AIM: Cytokine release syndrome is a dangerous complication of the coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety of tofacitinib in the management of this complication. METHODS: The retrospective study included COVID-19 patients with C-reactive protein (CRP) levels of 60–150 mg/L. RESULTS: Thirty-two patients who received tofacitinib (TOF group) and 30 patients who did not receive any anti-cytokine drugs (control [CON] group) were enrolled. Mortality and the incidence of admission to the intensive care unit were lower in the TOF group than in the CON group (16.6% vs. 40.0%, p = 0.009; and 15.6% vs. 50.0%, p = 0.004). There was a significant decrease in the volume of the affected part of the lungs (p = 0.022) and a significant increase in oxygen saturation (p = 0.012) in the TOF group than in the CON group 7–10 days after the beginning tofacitinib administration. CRP level was lower in the TOF group than in the CON group (7 [3–22] vs. 20 [5–52] mg/L; p = 0.048) 7–10 days after the start of the administration of tofacitinib. During this period, the number of patients requiring mechanical ventilation or those in the prone position increased in the CON group compared to those in the TOF group (26.7% vs. 0.0%, p = 0.002; 33.3% vs. 6.7%, p = 0.020). There was no significant difference in the development of secondary infections, liver or kidney injury, and cytopenia between the two groups. CONCLUSION: Tofacitinib was effective and safe for managing the cytokine release syndrome in COVID-19. Randomized controlled double-blind trials with tofacitinib with and without the simultaneous use of glucocorticoids are required to confirm our findings. Elsevier Ltd. 2021-08 2021-05-21 /pmc/articles/PMC8137353/ /pubmed/34023513 http://dx.doi.org/10.1016/j.pupt.2021.102039 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Maslennikov, Roman Ivashkin, Vladimir Vasilieva, Ekaterina Chipurik, Maxim Semikova, Polina Semenets, Victoria Russkova, Tatyana Levshina, Anna Grigoriadis, Diana Magomedov, Shamil Efremova, Irina Dzhakhaya, Natiya Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19 |
title | Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19 |
title_full | Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19 |
title_fullStr | Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19 |
title_full_unstemmed | Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19 |
title_short | Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19 |
title_sort | tofacitinib reduces mortality in coronavirus disease 2019 tofacitinib in covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137353/ https://www.ncbi.nlm.nih.gov/pubmed/34023513 http://dx.doi.org/10.1016/j.pupt.2021.102039 |
work_keys_str_mv | AT maslennikovroman tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 AT ivashkinvladimir tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 AT vasilievaekaterina tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 AT chipurikmaxim tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 AT semikovapolina tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 AT semenetsvictoria tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 AT russkovatatyana tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 AT levshinaanna tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 AT grigoriadisdiana tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 AT magomedovshamil tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 AT efremovairina tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 AT dzhakhayanatiya tofacitinibreducesmortalityincoronavirusdisease2019tofacitinibincovid19 |